Persons with multiple sclerosis older than 55 years: an analysis from the German MS registry

Yasemin Goereci,David Ellenberger,Paulus Rommer,Veronika Dunkl,Heidrun Golla,Uwe Zettl,Alexander Stahmann,Clemens Warnke

DOI: https://doi.org/10.1007/s00415-024-12286-4

2024-03-23

Journal of Neurology

Abstract:Background Persons with MS (PwMS) ≥ 55 years are underrepresented in therapy studies leading to a lack of evidence. Objective and methods To study the subgroup of PwMS ≥ 55 years in the German MS registry in comparison with PwMS < 55 years. Endpoints of interest were the grade of disability, leading symptoms, clinical and magnetic resonance imaging activity, and use of disease modifying therapy. Results At the time of analysis, data from 40,428 PwMS were available for analysis. In PwMS aged ≥ 65 and PwMS aged ≥ 55 to 64 years, compared with PwMS aged < 55 years, the mean Expanded Disability Status Scale Scores were higher (5.3, 4.2 and 2.7, respectively), while the proportion of individuals with current use of disease modifying therapy was lower (42.6%, 60.9% and 76.7%, respectively). The older patient groups were more likely to be labeled with progressive MS and the frequency of occupational invalidity was high (38.8% in PwMS aged ≥ 55 to 64 years). Gait disorder, fatigue, bladder dysfunction, and spasticity were among the leading symptoms in PwMS aged ≥ 55 years. Conclusion PwMS ≥ 55 years have a high degree of disability, but a large proportion do not receive disease modifying therapy, exposing an unmet need.

clinical neurology